Transparency Council meetings may be attended by experts in the medical field covered by the motions or information discussed during the meeting, as well as other individuals invited by the Chairperson of the Transparency Council as guests of the Transparency Council without a right to vote.
Submission of a Conflict of Interest Statement (CIS) referred to in Article 31s section 9 of the Act dated 27 August 2004 on healthcare services financed from public funds (Polish Journal of Laws of 2020, item 1398, as amended) is an absolute prerequisite for participation in the meeting.
A request for participation in a given Transparency Council meeting shall be submitted to the Agency not later than 5 days before the scheduled meeting date. For the dates of upcoming Council meetings and the subjects to be discussed, please refer to the Transparency Council work schedules and the agendas published in the Public Information Bulletin and in the News section.
A request for participation should include, among others:
- the Transparency Council meeting date,
- the subject to be discussed by the Council (name of the medicinal product/foodstuff for particular nutritional uses/medical device + indication/name of the service),
- the personal data and contact details of the individual requesting participation,
- information on any relationships with marketing authorization holders for the health technologies to be assessed by the Transparency Council.
If you have any concerns related to completing this form or the declarations below, please contact the Agency’s Councils Support Division: phone 22 101 46 33/34.
Should any circumstances arise that may give grounds for reasonable doubts as to the impartiality of the individual requesting participation in the meeting or of the institution they represent, the Chairperson of the Transparency Council may refuse to consent to their participation in the meeting.
Form for individuals requesting participation in the Transparency Council meeting:
*Ladies and Gentlemen
We inform you that the materials and results of the discussions posted on the Agency’s website are the result of the conceptual work and analytical process carried out by the team of the Agency for Health Technology Assessment and Tariff System based on the EBM paradigm, including: search, selection, synthesis and interpretation of scientific evidence, or the data analysis carried out .
In connection with the above, we would like to inform you that the use of analytical material or the results of the discussion, in accordance with good practice, should be accompanied by information on the source in the form: [title of presentation / report], AOTMiT, Warsaw, June 2021]